Médunik Canada becomes exclusive distributor of INCRELEX® in Canada, strengthening support for children with a rare growth disorder

14 Jul 2026
www.prnewswire.com
Orphan Drug
BLAINVILLE, QC, July 14, 2026 /PRNewswire/ - Médunik Canada, a Canadian owned and operated pharmaceutical company dedicated to improving the health and quality of life of people living with rare and debilitating diseases, part of Duchesnay Pharmaceutical Group, is pleased to announce that it has become the exclusive distributor of INCRELEX® (mecasermin), a recombinant human insulin-like growth factor-1 (rhIGF-1), in Canada. This significant milestone aims to support continuity of supply of this important treatment for Canadian patients affected by this rare disease.
Continue Reading
Médunik Canada is now exclusive distributor of Increlex in Canada
Médunik CanadaIGF-1) therapy is indicated for tIncrelexment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD). SPIGFD is an ultra-rare endocrine disorder characterized by the body's inability to produce adequate levels of insulin-like growth factor-1 (IGF-1), a hormone essential for normal childhood growth. Without appropriate treatment, children with SPIGFD might experience severely impaired growth, which can lead to significant short stature and its associated physical and emotional challenges.
MecaserminthrhIGF-1sive distributor of INCRELEX® in Canada is agrowth failuresion of Médunik Canada's mission to improve the lives of patients with rare coinsulin-like growth factor-1 deficiency (SPIGFD)insulin-like growth factor-1endocrine disorderinsulin-like growth factor-1 (IGF-1)short stature
said Carla LétourneauINCRELEXMédunik Canada
Director, Marketing Strategy, Médunik Canada.
"Children living with severe primary IGF-1 deficiency face unique diagnostic and treatment challenges. We are proud to partner with ESTEVE to ensure continued access to this important therapy and to support families throughout their treatment journey."
ESTEVE, a global pharmaceutical compaIGF-1 deficiencyIGF-1cused on delivering highly specialized treatments, partnered with Médunik Canada to distribute mecasermin (rhIGF-1) nationally, recognizing its established expertise in rare diseases and patient-centered support programs.
ESTEVEt of the transition, Médunik Canada will maintain the existing patient support program, helping to ensMédunik Canadated services fomecasermin (rhIGF-1)ivers.
"Early and accurate diagnosMédunik Canadarimary IGF-1 deficiency is critical to achieving optimal outcomes,"
said Dr Cheri Deal, Ph.D., M.D., Pediatric EndocIGF-1 deficiencyIGF-1ogist, CHU Sainte-Justine.
"Having a therapy like INCRELEX®, combined with comprehensivCHU Sainte-Justineand education, makes a meaningful difference for children who have limited treatment options. This partnership represents an important step forward for patients and healthcare providers."
Through this collaboratINCRELEXunik Canada and ESTEVE reaffirm their shared commitment to supporting patients with rare diseases and the healthcare professionals who serve them across Canada.
ABOUT MÉDUNIK CANADAMédunik CanadaESTEVE
Médunik Canada's vision is to improve the health and quality of life of Canadians living with a rare and debilitating disease. Founded in December 2009, and part of Duchesnay Pharmaceutical Group, the company provides access to orphan drugs through strategic global partnerships as well as domestic and international research and development projects.
Médunik Canadamation about Médunik Canada, please visit https://medunikcanada.com/en/ .Duchesnay Pharmaceutical Group
Follow us on LinkedIn
ABOUT DUCHESNAY PHARMACEUTICAL GROUP
Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Médunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries.
Duchesnay Pharmaceutical Group (DPG)ross the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate iDuchesnay to become an Duchesnay USAn the Canadian economy.Médunik CanadaMedunik USAAnalog Pharma CanadaAnalog PharmaDPG
DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem.
DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in womDPGs health, urology, oncology and for rare diseases, plus lower-cost generic medicDPGons. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
For more information, please visitoncology
https://duchesnaypharmaceuticalgroup.com/en.
Follow us on
LinkedIn.
LinkedInédunik Canada
21%
more press release views with
Request a Demo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!